The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis by Hurley, Joanna J. et al.
?P?annotatePDF?v12
?
INSTRUCTIONS?ON?THE?ANNOTATION?OF?PDF?FILES?
To?view,?print?and?annotate?your?content?you?will?need?Adobe?Reader?version?9?(or?higher).?This?program? is?freely?
available? for? a? whole? series? of? platforms? that? include? PC,? Mac,? and? UNIX? and? can? be? downloaded? from?
http://get.adobe.com/reader/. The? exact? system? requirements? are? given? at? the? Adobe? site:?
.
?
Note:?Please?do?NOT?make?direct?edits?to?the?PDF?using?the?editing?tools?as?doing?so?could?lead?us?to?overlook?your?
desired?changes.? ?Rather,?please?request?corrections?by?using?the?tools? in?the?Comment?pane?to?annotate?the?PDF?
and?call?out?the?changes?you?are?requesting.??If?you?opt?to?annotate?the?file?with?software?other?than?Adobe?Reader?
then?please?also?highlight?the?appropriate?place?in?the?PDF?file. 
?
PDF?ANNOTATIONS?
Adobe?Reader?version?9? Adobe?Reader?version?X?and?XI?
When? you? open? the? PDF? file? using? Adobe? Reader,? the?
Commenting?tool?bar?should?be?displayed?automatically;? if?
not,?click?on?‘Tools’,?select?‘Comment?&?Markup’,?then?click?
on? ‘Show? Comment? &? Markup? tool? bar’? (or? ‘Show?
Commenting? bar’? on? the?Mac).? If? these? options? are? not?
available? in? your?Adobe? Reader?menus? then? it? is? possible?
that?your?Adobe?Acrobat?version?is?lower?than?9?or?the?PDF?
has?not?been?prepared?properly.?
(Mac)?
PDF?ANNOTATIONS?(Adobe?Reader?version?9)?
?
The?default? for? the?Commenting? tool?bar? is? set? to? ‘off’? in?
version?9.?To?change?this?setting?select?‘Edit?|?Preferences’,?
then? ‘Documents’? (at? left? under? ‘Categories’),? then? select?
the?option?‘Never’?for?‘PDF/A?View?Mode’.?
?
(Changing?the?default?setting,?Adobe?version?9)?
To?make?annotations?in?the?PDF?file,?open?the?PDF?file?using?
Adobe?Reader?XI,?click?on?‘Comment’.??
If?this?option? is?not?available? in?your?Adobe?Reader?menus?
then?it?is?possible?that?your?Adobe?Acrobat?version?is?lower?
than?XI?or?the?PDF?has?not?been?prepared?properly.?
?
This? opens? a? task? pane? and,? below? that,? a? list? of? all?
Comments? in? the? text.? These? comments? initially? show? all?
the?changes?made?by?our?copyeditor?to?your?file.?
?
?
http://www.adobe.com/products/reader/tech-specs.html
 
HOW?TO...?
Action? Adobe?Reader?version?9? Adobe?Reader?version?X?and?XI?
Insert?text??
? Click?the?‘Text?Edits’?button? ?on?the?
Commenting? tool? bar.? Click? to? set? the? cursor?
location? in? the? text? and? simply? start? typing.? The?
text?will? appear? in? a? commenting? box.? You?may?
also?cut?and?paste? text? from?another? file? into? the?
commenting?box.?Close?the?box?by?clicking?on?‘x’?in?
the?top?right?hand?corner.??
Click?the?‘Insert?Text’?icon? ?on?the?Comment?
tool?bar.?Click?to?set?the?cursor?location?in?the?text?
and? simply? start? typing.?The? text?will?appear? in?a?
commenting?box.?You?may?also?cut?and?paste?text?
from?another? file? into?the?commenting?box.?Close?
the?box?by?clicking?on?‘_’? ?in?the?top?right?hand?
corner.??
Replace?text??
Click?the?‘Text?Edits’?button? ?on?the?
Commenting? tool?bar.?To?highlight? the? text? to?be?
replaced,? click?and?drag? the? cursor?over? the? text.?
Then? simply? type? in? the? replacement? text.? The?
replacement?text?will?appear?in?a?commenting?box.?
You?may?also?cut?and?paste?text?from?another?file?
into? this? box.? To? replace? formatted? text? (an?
equation? for? example)? please? Attach? a? file? (see?
below).?
Click? the? ‘Replace? (Ins)’? icon? ? on? the?
Comment? tool? bar.? To? highlight? the? text? to? be?
replaced,? click?and?drag? the? cursor?over? the? text.?
Then? simply? type? in? the? replacement? text.? The?
replacement?text?will?appear?in?a?commenting?box.?
You?may?also?cut?and?paste?text?from?another?file?
into? this? box.? To? replace? formatted? text? (an?
equation? for? example)? please? Attach? a? file? (see?
below).?
Remove?text??
Click?the?‘Text?Edits’?button? ?on?the?
Commenting?tool?bar.?Click?and?drag?over?the?text?
to? be? deleted.? Then? press? the? delete? button? on?
your?keyboard.?The?text?to?be?deleted?will?then?be?
struck?through.?
Click? the? ‘Strikethrough? (Del)’? icon? ? on? the?
Comment?tool?bar.?Click?and?drag?over?the?text?to?
be?deleted.?Then?press?the?delete?button?on?your?
keyboard.? The? text? to? be? deleted? will? then? be?
struck?through.?
Highlight?text/?
make?a?
comment?
Click? on? the? ‘Highlight’? button? ? on? the?
Commenting?tool?bar.?Click?and?drag?over?the?text.?
To? make? a? comment,? double? click? on? the?
highlighted?text?and?simply?start?typing.?
Click? on? the? ‘Highlight? Text’? icon? ? on? the?
Comment?tool?bar.?Click?and?drag?over?the?text.?To?
make?a?comment,?double?click?on? the?highlighted?
text?and?simply?start?typing.?
Attach?a?file?
Click?on?the? ‘Attach?a?File’?button? ?on?the?
Commenting?tool?bar.?Click?on?the?figure,?table?or?
formatted? text? to? be? replaced.? A? window? will?
automatically?open?allowing?you?to?attach?the?file.?
To? make? a? comment,? go? to? ‘General’? in? the?
‘Properties’? window,? and? then? ‘Description’.? A?
graphic?will? appear? in? the? PDF? file? indicating? the?
insertion?of?a?file.?
Click? on? the? ‘Attach? File’? icon? ? on? the?
Comment? tool? bar.? Click? on? the? figure,? table? or?
formatted? text? to? be? replaced.? A? window? will?
automatically?open?allowing?you?to?attach?the?file.?
A?graphic?will?appear? indicating? the? insertion?of?a?
file.?
Leave?a?note/?
comment?? Click?on?the? ‘Note?Tool’?button? ?on?
the?Commenting?tool?bar.?Click?to?set?the?location?
of? the? note? on? the? document? and? simply? start?
typing.?Do?not?use?this?feature?to?make?text?edits.?
Click?on? the? ‘Add? Sticky?Note’? icon? ?on? the?
Comment?tool?bar.?Click?to?set?the? location?of?the?
note?on?the?document?and?simply?start?typing.?Do?
not?use?this?feature?to?make?text?edits.?
 
HOW?TO...?
Action? Adobe?Reader?version?9? Adobe?Reader?version?X?and?XI?
Review?? To? review? your? changes,? click? on? the? ‘Show’?
button? ? on? the? Commenting? tool?
bar.?Choose? ‘Show?Comments?List’.?Navigate?by?
clicking?on?a?correction? in?the? list.?Alternatively,?
double? click? on? any? mark?up? to? open? the?
commenting?box.??
Your?changes?will?appear?automatically? in?a? list?
below? the? Comment? tool? bar.? Navigate? by?
clicking?on?a?correction? in?the? list.?Alternatively,?
double? click? on? any? mark?up? to? open? the?
commenting?box.??
Undo/delete?
change??
?
To?undo?any? changes?made,?use? the? right? click?
button?on?your?mouse?(for?PCs,?Ctrl?Click?for?the?
Mac).? Alternatively? click? on? ‘Edit’? in? the?main?
Adobe? menu? and? then? ‘Undo’.? You? can? also?
delete?edits?using?the?right?click?(Ctrl?click?on?the?
Mac)?and?selecting?‘Delete’.?
To?undo?any? changes?made,?use? the? right? click?
button?on?your?mouse?(for?PCs,?Ctrl?Click?for?the?
Mac).? Alternatively? click? on? ‘Edit’? in? the?main?
Adobe? menu? and? then? ‘Undo’.? You? can? also?
delete?edits?using?the?right?click?(Ctrl?click?on?the?
Mac)?and?selecting?‘Delete’.??
?
SEND?YOUR?ANNOTATED?PDF?FILE?BACK?TO?ELSEVIER??
Save? the? annotations? to? your? file? and? return? as? instructed?by?Elsevier.?Before? returning,?please?ensure? you?have?
answered?any?questions?raised?on?the?Query?Form?and?that?you?have?inserted?all?corrections:?later?inclusion?of?any?
subsequent?corrections?cannot?be?guaranteed.??
FURTHER?POINTS??
? Any?(grey)?halftones?(photographs,?micrographs,?etc.)?are?best?viewed?on?screen,?for?which?they?are?optimized,?
and?your?local?printer?may?not?be?able?to?output?the?greys?correctly.??
? If?the?PDF?files?contain?colour?images,?and?if?you?do?have?a?local?colour?printer?available,?then?it?will?be?likely?that?
you?will?not?be?able?to?correctly?reproduce?the?colours?on?it,?as?local?variations?can?occur.??
? If?you?print?the?PDF? file?attached,?and?notice?some? ‘non?standard’?output,?please?check? if?the?problem? is?also?
present?on?screen.?If?the?correct?printer?driver?for?your?printer?is?not?installed?on?your?PC,?the?printed?output?will?
be?distorted.??
?
?
Our reference: YMGE 11063 P-authorquery-v9
AUTHOR QUERY FORMJournal: YMGE
Article Number: 11063Please e-mail your responses and any corrections to:
E-mail: j.s.porter@elsevier.comDear Author,
Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen
annotation in the PDF file) or compile them in a separate list. It is crucial that you NOTmake direct edits to the PDF using
the editing tools as doing so could lead us to overlook your desired changes. Note: if you opt to annotate the file with
software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of
your paper please return your corrections within 48 hours.
For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.
Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in
the proof.Location
in article
Query / Remark: Click on the Q link to find the query’s location in text
Please insert your reply or correction at the corresponding line in the proofIf there are any drug dosages in your article, please verify them and indicate that you have done so by
initialing this queryQ1 Please check spelling of names carefully. Although every effort is made to ensure accuracy, it is ultimately
your responsibility to proof these pages carefully, paying particular attention to spelling of authors’ names.Q2 Ref. 8ePlease provide complete publication information.Q3 Please confirm that given names and surnames have been identified correctly and are presented in the
desired order and please carefully verify the spelling of all authors' names.Please check this box or indicate
your approval if you have nocorrections to make to the PDF file ,Thank you for your assistance.
Q3
Q1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
5455
56ORIGINAL ARTICLEAbbr
mato
polyp
DISC
to th
Copy
0016
https
Rece
www
57
58
59
60The impact of chromoendoscopy for surveillance of the
duodenum in patients with MUTYH-associated polyposis and
familial adenomatous polyposiseviatio
us pol
osis; N
LOSUR
is publi
right ª
-5107/$
://doi.o
ived No
.giejo
61
62
63
64Joanna J. Hurley, MD,1,2 Laura E. Thomas, PhD,1 Sarah-Jane Walton, PhD,3 Siwan Thomas-Gibson, MD,3
Adam Haycock, MD,3 Noriko Suzuki, MD,3 Matthew Mort, PhD,1 Geraint Williams, PhD,4
Meleri Morgan, MD,4 Susan K. Clark, MD,3,5 Julian R. Sampson, DM,1 Sunil Dolwani, MD1,6
Cardiff, UK; Merthyr Tydﬁl, UK; Harrow, UK; London, UK
65
66
67Background and Aims: Duodenal polyposis and cancer have become a key issue for patients with familial
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP). Almost all patients with FAP will develop
duodenal adenomas, and 5% will develop cancer. The incidence of duodenal adenomas in MAP appears to be
lower than in FAP, but the limited available data suggest a comparable increase in the relative risk and lifetime
risk of duodenal cancer. Current surveillance recommendations, however, are the same for FAP and MAP, using
the Spigelman score (incorporating polyp number, size, dysplasia, and histology) for risk stratiﬁcation and deter-
mination of surveillance intervals. Previous studies have demonstrated a beneﬁt of enhanced detection rates of
adenomas by use of chromoendoscopy both in sporadic colorectal disease and in groups at high risk of colorectal
cancer. We aimed to assess the effect of chromoendoscopy on duodenal adenoma detection, to determine the
impact on Spigelman stage and to compare this in individuals with known pathogenic mutations in order to deter-
mine the difference in duodenal involvement between MAP and FAP.
Methods: A prospective study examined the impact of chromoendoscopy on the assessment of the duodenum in
51 consecutive patients with MAP and FAP in 2 academic centers in the United Kingdom (University Hospital Llan-
dough, Cardiff, and St Mark’s Hospital, London) from 2011 to 2014.
Results: Enhanced adenoma detection of 3 times the number of adenomas after chromoendoscopy was demon-
strated in both MAP (PZ .013) and FAP (PZ .0.002), but did not affect adenoma size. In both conditions, there
was a signiﬁcant increase in Spigelman stage after chromoendoscopy compared with endoscopy without dye
spray. Spigelman scores and overall adenoma detection was signiﬁcantly lower in MAP compared with FAP.
Conclusions: Chromoendoscopy improved the diagnostic yield of adenomas in MAP and FAP 3-fold, and in both
MAP and FAP this resulted in a clinically signiﬁcant upstaging in Spigelman score. Further studies are required to
determine the impact of improved adenoma detection on the management and outcome of duodenal polyposis.
(Gastrointest Endosc 2018;-:1-8.)90
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TABLE 1. Modified Spigelman classification of duodenal polyposis in
FAP
1 point 2 points 3 points
No. of polyps 1-4 5-20 >20
Polyp size (mm) 1-4 5-10 >10
Histology Tubular Tubulovillous Villous
Dysplasia Low grade High grade
Stage 0, 0 points; stage I, 1 to 4 points; stage II, 5 to 6 points; stage III, 7 to 8 points;
stage IV, 9 to 12 points.
Surveillance of patients with MUTYH-associated polyposis and FAP Hurley et al
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211manifestations, including duodenal adenomas and cancer,
which in FAP have now become a leading cause of death
as patients undergo prophylactic colectomy at an early stage
in their disease. Duodenal polyposis is seen less frequently
inMAP than FAP, occurring in up to 17% to 34%1,2 compared
with 70% or more of patients with FAP,3 but the very limited
available data suggest a comparable increase in relative risk
and lifetime risk of duodenal cancer.
The Spigelman scoring system (Table 1) for risk
stratiﬁcation of duodenal polyps in FAP was developed to
allow an estimation of the risk of developing duodenal
carcinoma and guide surveillance intervals.4 The Mallorca
group advocated the same upper GI surveillance program
for MAP.3 In FAP, the risk of developing cancer in Spigelman
stages III to IV is reported to be between 7% and 36%
despite an overall cancer risk in all patients of 5%. Recent
data suggest this risk may be even higher with 1 study
reporting a lifetime risk of duodenal carcinoma of 18%.5
Accurately identifying patients at increased risk of harboring
or developing duodenal cancer is the principal goal of
surveillance but, because many patients with FAP develop
duodenal polyps, yet most patients do not develop invasive
cancer, the clinical management remains problematic. There
are few published data on the natural history of duodenal
adenomatosis in MAP, and only 1 retrospective study
describing 92 patients undergoing upper GI surveillance.2
In the colon, there is an overall polyp miss rate of 22%
using white-light endoscopy for sporadic polyps6 and many
studies that have examined the impact of pan-
chromoendoscopy on polyp detection rates. A Cochrane
review of chromoendoscopy excluding patients with polyp-
osis syndromes and inﬂammatory bowel disease concluded
that chromoendoscopy identiﬁes more patients with at
least 1 adenoma and signiﬁcantly more patients with 3 or
more adenomas.7 The detection or miss rate of lesions
within the upper GI tract has not been as widely studied,
and rarely in the duodenum. Moreover, many of the
factors associated with miss rates in the colon are not
applicable to upper GI endoscopic examination.
The effect of chromoendoscopy on duodenal adenoma
detection in MAP has not been investigated. This study
aims to evaluate the use of dye spray with indigo carmine
in the duodenum to improve the identiﬁcation of polyps
that may be overlooked during standard white-light endo-
scopic examination. It also aims to determine the impact of
dye spray on Spigelman stage and to compare this in indi-
viduals with MAP and FAP.212
213
214
215
216
217
218
219
220METHODS
The research was approved by the South-East Wales
research ethics committee in January 2010 (reference
number 10-MRE09-43) and the North West London Hospi-
tals NHS Trust (reference number RD12/078). Cases for
the study were recruited prospectively. Patients with2 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2018
FLA 5.5.0 DTD  YMGE11063_pconﬁrmed FAP or MAP on genetic testing were recruited
from University Hospital Llandough, Cardiff, UK, the Insti-
tute of Medical Genetics, University Hospital of Wales, Car-
diff, UK, and St Marks Hospital, Harrow, UK. All patients
gave informed consent. There were no healthy volunteer
controls recruited for the study. Between August 2011
and January 2014, 51 consecutive patients scheduled for
surveillance endoscopy of the upper GI tract were invited
to participate in the study. The endoscopies were per-
formed in 2 academic centers in the UK (University Hospi-
tal Llandough, Cardiff, and St Mark’s Hospital, London).
At each center, experienced endoscopists performed all
endoscopies for this study (S.D., J.H., A.H., and N.S.) using
high-resolution forward-viewing video endoscopes (GIF-
Q260, GIF-H260, GIF XQ260; Olympus Medical Systems)
and a side-viewing duodenoscope for optimal visualization
of the ampulla. Procedures were performed with the pa-
tients under general anesthetic (propofol) or conscious
sedation using standard doses of fentanyl and midazolam
in line with British Society of Gastroenterology guidance,8
depending on patient preference and the presence of co-
morbid conditions. Antispasmodic medication (hyoscine
butylbromide) was given during endoscopy at the discre-
tion of the endoscopist.
At introduction, the forward-viewing endoscope was
advanced until the duodeno-jejunal junction was reached.
During withdrawal, the different parts of the duodenum
(D2, D3, and duodenal bulb) were evaluated, and the num-
ber and sizes of polyps recorded on a standardized pro-
forma before staining with indigo carmine dye (Fig. 1).
Polyp size was estimated using Radial Jaw 3 biopsy
forceps (Boston Scientiﬁc, Natick, Mass), with a closed
diameter of 2.2 mm and an open diameter of 8 mm. The
endoscopist then sprayed a 0.3% solution of indigo
carmine (3 mL of indigo carmine 1% and 7 mL of water
for injection) from D3 proximally to the duodenal bulb
onto the duodenal mucosa, distributed in a
homogeneous fashion by a spraying catheter passed
through the endoscope channel. The residual dye was
then suctioned away. After adequate coating of the
duodenum with the dye solution, a second endoscopist
unaware of the ﬁndings and polyp count from the ﬁrst
part of the examination, recorded the size and number
of polyps seen (Fig. 2). Biopsy samples were not takenwww.giejournal.org
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Figure 1. Duodenum of a patient with 1999 before chromoendoscopy. p
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Figure 2. Duodenum of the same patient with FAP after
chromoendoscopy.
Hurley et al Surveillance of patients with MUTYH-associated polyposis and FAP
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320until after staining and counting had taken place. Samples
were taken from all lesions with high-grade morphology
(disrupted surface pattern, ulceration, or depressed areas
within the polyp) and lesions greater than 1 cm. If the
number of polyps was small, all lesions were sampled,
but if there were numerous polyps, at least 3 of the largest
adenomas were sampled in addition to the criteria above.
To further aid accurate staging of duodenal disease, our
protocol asked for examination using a side-viewing endo-
scope in patients where the ampulla was inadequately visu-
alized using the forward-viewing endoscope. If it appeared
adenomatous, biopsy specimens were taken. All proced-
ures were conducted using the same structural and color
enhancement settings in both centers.
For all patients, Spigelman point totals and stage before
and after the application of chromoendoscopy were as-
sessed. The following criteria were used: number of ade-
nomas, largest size, the most advanced histology, and
most advanced grade of dysplasia. All lesions sampled for
histology were conﬁrmed as adenomas. The biopsy speci-
mens were evaluated by 2 expert gastrointestinal patholo-
gists (M.M. and G.T.W.) who graded dysplasia according to
the Vienna (low-grade/high-grade) classiﬁcation9 and the
3-tier grading system used by Spigelman et al.4321
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331
332Statistical analysis
Statistical analysis for the study was performed using
R (version 3.0.2) software. Statistical signiﬁcance for the
frequency of duodenal adenomas was calculated using
the Wilcoxon signed-rank test and Mann-Whitney U test,
and a one-sided sign test was used to compare the Spigel-
man stages. A P value of less than .05 was considered sta-
tistically signiﬁcant. The study was powered for 92% at a
5% signiﬁcance level to detect a difference in the number
of polyps in MAP versus FAP (1 degree of freedom using awww.giejournal.org
FLA 5.5.0 DTD  YMGE11063_pchi-squared test to compare the 2 conditions). Statistical
data are expressed as medians.RESULTS
Between August 2011 and January 2014, 51 patients (19
FAP and 32 MAP) underwent gastroduodenoscopies. Of
the FAP patients, 8 were female and 11 were male; median
age was 41 years (range, 32-69 years). There were 17
female and 15 male patients with MAP; median age 54
years (range, 25-81 years). No patient was on any pharma-
cological treatments for their duodenal disease or for their
colonic disease. There were no adverse events relating to
endoscopic examination (bleeding or perforation), and
no adverse events relating to general anesthesia or seda-
tion were observed.
Patients in the MAP group were signiﬁcantly older than
those with FAP (P Z .0.001). There was no difference in
the calculated overall Spigelman stage before or after dye
spraying for any patient when comparing the traditional
3-tiered grading system with the modiﬁed (Vienna classiﬁ-
cation) Spigelman score.
Number of adenomas
In MAP patients before staining, 10 lesions were found in
32 patients (range, 0-6), and this increased signiﬁcantly to
34 lesions after dye spraying (range, 0-15) (Table 2).
Additional duodenal adenomas were detected in 9
patients (28%). The median number of additional
adenomas detected was 2 per patient (total, 24; range, 1-9).
The median number of adenomas in the FAP cohort
with white light, per patient, was 4 (total, 150; range,
0-46). After staining, the median number of adenomas
detected was 14 per patient (total, 442; range, 0-100)Volume -, No. - : 2018 GASTROINTESTINAL ENDOSCOPY 3
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TABLE 2. Duodenal adenoma characteristic in patients with MAP
(n [ 32)
Gastroduodenoscopy
findings Pre-staining Post-staining
P
value
Median number of
duodenal adenomas
(total)
0 (10) 0 (34) .01368*
Largest size (mm),
median (range)
5 (2-50) 6 (2-50) .3711
Spigelman stage,
median (range)
0 (0-III) 0 (0-III) .03125*
Despite no change in the median Spigelman scores, the Mann-Whiney and Wilcoxon
tests are rank sum tests and not median tests. It is possible for groups to have
different rank sums and yet have equal or nearly equal medians.
*Statistically significant difference (P < .05).
TABLE 3. Duodenal adenoma characteristics in patients with FAP
(n [ 19)
Gastroduodenoscopy
findings
Pre-
staining
Post-
staining P value
Number of duodenal
adenomas, median
(total)
4 (150) 14 (442) .002516*
Largest size (mm),
median (range)
6 (2-23) 6 (2-30) .1814
Spigelman stage,
median (range)
II (0-IV) II (0-IV) .03125*
*Statistically significant difference (P < .05).
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444(P Z .0.002) (Table 3). Additional adenomas after
chromoendoscopy were detected in 13 patients (68% of
FAP cases).
The number of duodenal adenomas observed after
staining was signiﬁcantly higher in FAP than MAP
(P Z .0002452; Mann-Whitney U test).
Size of adenomas
The median largest adenoma size was 5 mm compared
with 6 mm after dye spray in MAP, and the size of the
largest adenomas (15 mm, 15 mm, 25 mm, and 50 mm)
did not change after dye spraying with indigo carmine.
In FAP, there was also no statistically signiﬁcant change
in the median adenoma size after staining. No statistically
signiﬁcant difference was observed between the post-
staining size of the largest duodenal adenomas observed
in MAP versus FAP (P z 1; Mann-Whitney U test). There
was no signiﬁcant statistical difference in the overall
numbers of adenomas greater than 1 cm in patients with
MAP versus FAP before or after staining (P z 1; Mann-
Whitney U test).
The numbers of polyps of different sizes detected after
chromoendoscopy in MAP and FAP are given in Tables 4
and 5.
Histology of adenomas
All polyps in patients with MAP were tubular adenomas
with low-grade dysplasia. Three patients had moderate-
grade dysplasia when assessed according to the 3-grade
system used by Spigelman et al.4 Among the cases of
FAP, there were tubular adenomas in 8 patients (42%),
tubulovillous adenomas in 4 patients (21%), and villous
adenoma in 1 patient (5%), all with low-grade dysplasia.
Four of the patients with FAP had moderate dysplasia ac-
cording to the Spigelman criteria,4 with no high-grade
dysplasia (HGD) detected.
Endoscopic technique
Use of the side-viewing endoscope did not detect any
additional ampullary adenomas compared with the4 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2018
FLA 5.5.0 DTD  YMGE11063_pforward-viewing endoscope, and only 1 patient had an
ampullary adenoma detected in this study. One patient
was observed to have 4 further polyps detected by side-
viewing endoscopy after dye spraying and counting.
Twenty-three patients (45%) of the total cohort of 51
required side-viewing endoscopy to ensure clear ampullary
visualization.
Spigelman staging
Before dye spraying, the Spigelman classiﬁcation was
stage 0 in 27 patients (84%), stage I in 2 patients
(6.25%), stage II in 2 patients (6.25%), and stage III in 1 pa-
tient (3.5%) with MAP (Table 6). Staining resulted in an
increased Spigelman point total in 9/32 individuals (28%),
with a corresponding upgrade in Spigelman stage in 6
patients (18%) (from 0 to I, n Z 1; from 0 to II, n Z 3;
from I to II, n Z 2; P < .05). Among the patients with
FAP, staining resulted in an increased Spigelman point
total in 13 of 19 individuals (68%), with a corresponding
upgrade in Spigelman stage in 5 patients (26%) (from
0 to I, n Z 1; from I to II, n Z 1; from I to IIII, n Z 2;
from III to IV, n Z 1; P < .05).
The post-staining Spigelman stage is signiﬁcantly higher
in FAP versus MAP (P Z .0009646; Mann-Whitney U test).
The change in Spigelman grade reﬂected the increased
number of adenomas detected.
Mutation data
The mutation analysis of the 32 patients with MAP and
the total number of duodenal adenomas detected are pre-
sented in Table 7.DISCUSSION
This study is the ﬁrst to assess the impact of chromoen-
doscopy in the evaluation of duodenal adenomas in pa-
tients with MAP, a group in which upper GI disease has
not been extensively studied, and compares this to the
ﬁndings in patients with FAP. Potential applications of
chromoendoscopy within the upper GI tract in FAP appear
promising; the diagnostic yield of standard surveillancewww.giejournal.org
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TABLE 4. Adenoma numbers by size pre-and post-staining in MAP
Case
No. of polyps
1-4 mm 5-10 mm >10 mm
Pre-staining Post-staining Pre-staining Post-staining Pre-staining Post-staining
1-3, 5-11, 14, 16, 17, 22, 24-27, 29-32 0 0 0 0 0 0
4 0 1 0 0 0 0
12 0 6 2 6 2 2
13 0 0 0 1 0 0
15 1 2 1 1 0 0
18 0 0 1 1 0 0
19 0 0 1 2 0 0
20 0 1 0 1 1 1
21 0 0 0 1 1 1
23 0 2 0 1 0 0
28 0 3 0 1 0 0
TABLE 5. Number of adenoma by size pre-and post-staining in FAP
Case
No. of polyps
1-4 mm 5-10 mm >10 mm
Pre-staining Post-staining Pre-staining Post-staining Pre-staining Post-staining
33-34, 41-42, 48-49 0 0 0 0 0 0
35 3 10 4 7 0 0
36 14 34 5 22 5 5
37 0 1 0 0 0 0
38 8 19 10 18 0 0
39 1 13 5 8 0 0
40 1 3 2 3 0 0
43 29 81 14 23 3 3
44 8 53 4 21 2 2
45 0 6 0 2 0 0
46 5 6 1 25 4 4
47 4 12 0 4 0 0
50 2 4 8 10 0 0
51 4 11 3 15 0 0
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556upper GI endoscopy was demonstrated to be improved by
dye spraying alone in a small study of 10 patients with FAP
undergoing upper GI endoscopic surveillance.10 A more
recent study of 43 patients also demonstrated that
chromoendoscopy increased the detection of duodenal
adenomas in FAP but did not lead to a considerable
change in the Spigelman stage.11
This study demonstrates that there is a signiﬁcant in-
crease in the numbers of duodenal adenomas identiﬁed af-
ter indigo carmine dye spraying in cases of both MAP and
FAP, and that this resulted in a signiﬁcant increase in thewww.giejournal.org
FLA 5.5.0 DTD  YMGE11063_pSpigelman stage in both conditions. This study identiﬁed
duodenal adenomas in 28% of patients with MAP, similar
to the series recently reported by Walton et al2 who
identiﬁed duodenal adenomas in 34% of patients with
MAP, and higher than the 17% observed in a previous
multicenter European study.1
Two previous studies have assessed adenoma number
while investigating the role of chromoendoscopy in the du-
odenum in FAP. Picasso et al10 studied 10 patients
undergoing upper GI surveillance and found a statistically
signiﬁcant increase in the number of duodenal polypsVolume -, No. - : 2018 GASTROINTESTINAL ENDOSCOPY 5
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TABLE 6. Distribution of Spigelman stages in patients with FAP and MAP before and after staining, compared with results reported in previous
case series of patients with FAP
Spigelman stage
Present series MAP (n [ 32), n (%) Present series FAP (n [ 19), n (%)
Previous case series11 (n [ 43
FAP), n (%)
Before staining After staining Before staining After staining Before staining After staining
0 27 (84) 23 (72) 7 (37) 6 (32) 3 (7) 2 (4)
I 2 (6.25) 1 (3) 2 (10) 1 (5) 2 (4) 2 (4)
II 2 (6.25) 7 (22) 4 (21) 4 (21) 11 (26) 10 (23)
III 1 (3.5) 1 (3) 3 (16) 4 (21) 14 (33) 15 (36)
IV 0 0 3 (16) 4 (21) 13 (30) 14 (33)
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668after chromoendoscopy (P Z .0.03), revealing additional
polyps in 8 of the 10 patients. Unlike our study, the
overall change in Spigelman stage was not assessed.
Dekker et al11 studied 43 patients with FAP and showed
that signiﬁcantly more duodenal adenomas were
detected after the application of indigo carmine, but this
did not result in a considerable change in Spigelman
stage or result in any major additional clinical
consequences. Of the 43 patients, only 26 had an APC
mutation that had previously been identiﬁed; the other
17 patients all had undergone colectomy because of
>100 histologically conﬁrmed colorectal adenomas but
without conﬁrmation of pathogenic mutations. In
contrast, our cohort of patients comprises a speciﬁc
subgroup with known mutations. In addition, the
endoscopist in Dekker et al.’s study was not blinded to
the number of adenomas before staining, which may
have biased the results. Although our current study was
designed to blind the second counting endoscopist,
there remains the possibility of a systematic bias due to
counting differences between the 2 endoscopists. Both
previous studies of dye spray duodenoscopy are in
agreement with our ﬁndings in FAP, but the impact on
adenoma detection in MAP has never been studied and
is a novel ﬁnding.
The small number of patients with MAP reported to
have developed duodenal cancer appear to have done so
on a background of minimal duodenal polyps,1 in
contrast to those with FAP, and it is not necessarily that
the total polyp number is as important as other factors in
the assessment of duodenal cancer risk in patients with
MAP. Recent molecular genetic analysis revealed a
greater burden of somatic mutations in MAP than in FAP
adenomas, suggesting the MAP-associated DNA repair
defect may drive a more rapid progression of adenoma
to cancer.12 Although none of the studies to date have
established the clinical interpretation of multiplicity of
duodenal adenomas in MAP, the improved adenoma
detection rate seen in MAP after chromoendoscopy in
this study has the potential to be clinically meaningful,
because it is likely to lead to more appropriate
surveillance intervals for some patients.6 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2018
FLA 5.5.0 DTD  YMGE11063_pGenerally, in studies of the outcomes of surgical inter-
vention in FAP, it is the patient’s Spigelman stage that
has been reported rather than the sizes of lesions
harboring cancer.5,13,14,15 Lopez-Ceron et al16 found that
when using narrow band imaging (NBI) for detection of
duodenal adenomas, the only trait that was signiﬁcantly
associated with advanced histology was an estimated
polyp size of greater than 1 cm, with a 3-fold increased
risk. Although high Spigelman stages do not necessarily
imply advanced histologic lesions, Saurin et al13 reported
that an original Spigelman score equal to or greater than
7 or 8 was predictive of HGD development. The use of
chromoendoscopy in the colon to highlight high-risk fea-
tures for biopsy, such as an advanced Kudo pit pattern,
which may be overlooked by white-light endoscopy, has
been described in the literature, and use of image
enhancement techniques (digital or chromoendoscopic)
can improve diagnostic accuracy in lesion assessment.17
In the duodenum, this may also be of direct beneﬁt to
identify advanced surface characteristics and enable
targeted biopsy.
This study has shown no signiﬁcant effect of chromoen-
doscopy on the sizing of adenomas in either MAP or FAP.
Dekker et al11 reported that the largest adenomas detected
at chromoendoscopy appeared signiﬁcantly larger than
before staining, possibly due to better visualization of the
adenoma borders. In contrast, Picasso et al10 reported
that polyps appeared smaller after dye spraying (P Z
.0.03), which was also explained by more precise
demarcation than normal. Although some lesions may
look larger or smaller after dye spray, the detection of
additional smaller lesions would of course result in a
smaller median size of polyps detected. Our study
suggests that, like NBI,16 chromoendoscopy does not
signiﬁcantly affect the apparent size of adenomas in the
FAP duodenum.
Dekker et al11 attributed the minor change in Spigelman
score in their study to the use of high-resolution endos-
copy. They concluded that considerably improved
endoscopic visualization of duodenal adenomatosis with
high-resolution endoscopy leaves little room for further
improvement of clinical consequence. However, thewww.giejournal.org
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TABLE 7. MAP mutation analysis data and number of duodenal
adenomas detected
Case Mutation 1 Mutation 2
Total number of duodenal
polyps detected
1 Y104X Y104X 0
2 G396D G396D 0
3 Y179C V130EfsX98 0
3 Y179C Y179C 1
5 E480X E480X 0
6 Y179C G396D 0
7 Y179C G396D 0
8 Y179C Y179C 0
9 Y179C G396D 0
10 Y104X Y104X 0
11 Y104X Y104X 0
12 Y179C Y179C 15
13 Y104X Y104X 1
14 Y104X Y104X 0
15 Y179C G396D 1
16 E466X E466X 0
17 E466X E466X 3
18 Gln 414 þ Gln
414 þ Tyr 104
1240 C>T þ
312 C>A
0
19 E466X E466X 0
20 E466X E466X 1
21 E480X E466X 3
22 E480X E466X 2
23 E480X E466X 0
24 E466X E466X 3
25 E480X E466X 0
26 E480X E466X 0
27 E466X E466X 0
28 Y179C Y179C 4
29 Y179C Y179C 0
30 E480X E466X 0
31 E480X E466X 0
32 Y179C R244X 0
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780endoscopist was not blinded to the number of adenomas
before staining. A previous study has suggested that in pa-
tients who have duodenal disease progression, both time
lapse and technical improvements were determinant fac-
tors.18 In a mixed-model analysis, time lapse, change to
high-resolution technology, and dysplasia ranking contrib-
uted consistently to an increased Spigelman score and
stage. This suggests visibility and histology may result in
an overestimation of the clinical signiﬁcance of duodenal
polyposis by using the Spigelman system. However, other
studies appear to demonstrate a lack of correlationwww.giejournal.org
FLA 5.5.0 DTD  YMGE11063_pbetween the ﬁndings at endoscopy and pathology results
from biopsy specimens, and between progressive struc-
tural changes within the polyps and pathology ﬁndings.19
This led the authors to argue that the overall aim of
identifying patients who are at high risk of developing
duodenal and ampullary cancer remains problematic.
Currently, there is no comprehensive picture of the risk
of duodenal adenomas and cancer in patients with MAP,
and the risks of duodenal disease remains uncertain.
Further research is required to prospectively validate the
Spigelman classiﬁcation in the risk stratiﬁcation of
duodenal polyposis, because its suitability for MAP has
not been established.
Lopez-Ceron et al16 are the only group to have
evaluated the effect of NBI (after examination with high-
resolution endoscopy) on the detection rates of duodenal
adenomas in patients with FAP. In contrast to this current
study, they found that in their study group of 37 patients,
there was no clinically relevant upgrade in the Spigelman
classiﬁcation using NBI. They also concluded that there
was no improvement in the detection of gastric polyps us-
ing NBI. More duodenal adenomas were detected in 16 ex-
aminations (35.6%), but Spigelman stage increased in only
2 patients (2.2%), which was not statistically signiﬁcant.
The current study therefore supports the use of chro-
moendoscopy over NBI in the improvement of adenoma
detection in duodenal polyposis, but larger prospective
studies are needed to conﬁrm this.
The patients with MAP in this study were signiﬁcantly
older than the patients with FAP. In patients with FAP,
time since diagnosis, age, and Spigelman stage at initial
endoscopy have been found to be determining features of
the severity of duodenal polyposis.3,13,20,21 These variables
may not apply for MAP. Our study suggests that the effect
of increasing age on the number of polyps is not the same
for MAP as it is for FAP. The natural history of duodenal pol-
yposis in MAP is a topic that requires further study.
A limitation of this study is the inability to determine the
additional value of chromoendoscopy in the assessment of
ampullary adenomas; because examination of this area
with the side-viewing endoscope was done after dye
spaying had taken place (current recommendations sug-
gest use of a side-viewing duodenoscopy as standard).
We found that almost half of the patients required further
side-viewing endoscopy to satisfactorily visualize the
ampulla, suggesting this should continue to be included
in protocols for duodenal surveillance. In addition, our
study was not designed to systematically assess the utility
of side-viewing endoscopy itself on the number of polyps
in the peri-ampullary region. A previously reported case se-
ries found ampullary adenomas in 66% of patients with FAP
when using a side-viewing endoscope,22 however our
study did not detect many ampullary adenomas (only 2
patients had ampullary adenomas), which may have
caused bias because most malignancies occur in the
periampullary region. No lesions with HGD wereVolume -, No. - : 2018 GASTROINTESTINAL ENDOSCOPY 7
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853detected, and our series may not be representative of the
FAP and MAP population although it involves 2 large UK
centers with relatively high-volume surveillance caseloads
for polyposis. In their prospective ﬁve-nation study of the
long-term natural history duodenal adenomas in FAP, Bu-
low et al21 reported that 12% of adenomas were
diagnosed only histologically, where no visible polyps
were seen. The current study did not incorporate taking
routine biopsy specimens of the background duodenal
mucosa to exclude dysplasia and relied on visualization
of precisely demarcated adenomatous tissue as
morphologic polyps. Picasso et al10 did take random
biopsy specimens of mucosal folds in the second and
upper third part of the duodenum, including the papilla,
but found no additional adenomatous tissue. Dekker
et al11 did not include taking random background biopsy
specimens in their protocol.854
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876CONCLUSIONS
This study demonstrates that chromoendoscopy of the
duodenum enhances adenoma detection in both MAP
and FAP, and that use of a side-viewing endoscope is
essential to ensure that the ampulla is adequately visual-
ized. In both conditions, there was a signiﬁcant increase
in Spigelman stage after chromoendoscopy and therefore
of clinical consequence to the patient in terms of follow-
up according to current management guidelines. The in-
crease in Spigelman stage was due to increased detection
of numbers of polyps rather than by enlarged polyps or
high-grade adenomas. Because screen-detected duodenal
cancers have been shown to have a much better prognosis
than symptomatic cancers in FAP (overall survival of 8 years
after a screen-detected cancer versus 0.8 years5), there is a
strong argument for regular endoscopic surveillance.
However, there are shortcomings in applying the same
surveillance program to MAP as for FAP because of a
paucity of knowledge of the risk of malignant
progression in MAP duodenal adenomas. Further studies
are needed to focus on this question.877
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